Cargando…
A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease
Gaucher disease (GD), the most common lysosomal storage disorders, is caused by GBA gene mutations resulting in glycosphingolipids accumulations in various tissues, such as the brain. While suppressing glycosphingolipid accumulation is the central strategy for treating peripheral symptoms of GD, the...
Autores principales: | Fujii, Takahiro, Tanaka, Yuta, Oki, Hideyuki, Sato, Sho, Shibata, Sachio, Maru, Takamitsu, Tanaka, Maiko, Onishi, Tomohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293090/ https://www.ncbi.nlm.nih.gov/pubmed/34398463 http://dx.doi.org/10.1111/jnc.15492 |
Ejemplares similares
-
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016) -
A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice
por: Onishi, Tomohiro, et al.
Publicado: (2021) -
Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014) -
Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
por: Cabrera-Salazar, Mario A., et al.
Publicado: (2012) -
Glucosylceramide synthase maintains influenza virus entry and infection
por: Drews, Kelly, et al.
Publicado: (2020)